Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01058941 · ClinicalTrials.gov registry record · Phase 1
Lipoic Acid and Omega-3 Fatty Acids for Alzheimer's Disease
A Phase 1 study, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- Phase 1
- Development phase
- 67
- Enrollment target
NCT01058941 is a Phase 1 study that has completed, run by Oregon Health and Science University. The registered enrollment target is 67 participants.
The verdict
NCT01058941, a Phase 1 study, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 67 participants
- Enrollment target
Study Summary
The purpose of this study was to see if taking lipoic acid plus omega-3 fatty acids (omega-3s) can slow the Alzheimer's disease (AD) process. To see if the treatment can slow the AD process, the investigators looked at changes in memory and changes in a person's daily activities over 18 months.
Interventions
- DRUG Placebo
- DRUG Lipoic acid and fish oil concentrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2010-09 |
| Est. Completion | 2014-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01058941
The ClinicalTrials.gov registry entry for NCT01058941 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01058941 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01058941 about?
NCT01058941 is a clinical study titled "Lipoic Acid and Omega-3 Fatty Acids for Alzheimer's Disease". The purpose of this study was to see if taking lipoic acid plus omega-3 fatty acids (omega-3s) can slow the Alzheimer's disease (AD) process. To see if the treatment can slow the AD process, the investigators looked at changes in memory and changes in a person's daily activities over 18 months.
What is the current status of trial NCT01058941?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 67 participants. The study started on 2010-09. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01058941?
The interventions under investigation include: Placebo (DRUG), Lipoic acid and fish oil concentrate (DRUG).
Who is sponsoring clinical trial NCT01058941?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.